Ignite Creation Date:
2025-12-24 @ 12:11 PM
Ignite Modification Date:
2026-01-04 @ 8:59 AM
Study NCT ID:
NCT02941861
Status:
COMPLETED
Last Update Posted:
2016-10-21
First Post:
2016-10-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Factors Influencing the 3-Year Recurrence of Liver Carcinoma After Surgery
Sponsor:
Ruechuta Molek
Organization:
Study Overview
Official Title:
Factors Influencing the 3-Year Recurrence of Liver Carcinoma After Surgery
Status:
COMPLETED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Objective:
1. To study the factors that influence the 3- year recurrence of liver carcinoma after surgery
2. To study the related factors affecting recurrence of liver carcinoma after surgery
1. To study the factors that influence the 3- year recurrence of liver carcinoma after surgery
2. To study the related factors affecting recurrence of liver carcinoma after surgery
Detailed Description:
Liver carcinoma including 80% Hepatocellular carcinoma (HCC) and 20% Cholangiocarcinoma (CCA) becomes the leading causes of death in East and South-East Asia. Though hepatectomy is the treatment of choice for early stage cancer, the recurrence has been reported as 30%, 62% and 79% in 1st, 3rd and 5th year respectively. Chulabhorn hospital, a cancer institute established in 2011, has been performing a 3-years retrospective study on the influencing factors and its correlation to liver carcinoma after surgery.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: